Skip to content Skip to footer
Subscribe Now
Viewpoints_Megan Bailey
VIEWPOINTS

PharmaShots Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac

In an interview with PharmaShots, Megan Bailey, CEO of PGDx shared her views on PGDx's collaboration with QIAGEN and Almac to advance cancer diagnostics and make precision medicine more accessible to healthcare systems, laboratories, and patients globally.Shots:On Jan 11, 2021, PGDx and Almac collaborated to enhance patient care in the oncologyOn Jan 13, 2021, PGDx collaborated…
March 3, 2021

Read more

Viewpoints_Tillman Gerngross
VIEWPOINTS

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2.Shots:ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014)The company expects ADG20 to enter clinical studies…
March 1, 2021

Read more

Viewpoints_Mark Gurney
VIEWPOINTS

PharmaShots Interview: Tetra Therapeutics’ Mark Gurney Shares Insight on Topline Results of BPN14770 for Fragile X Syndrome

In an interview with PharmaShots, Mark Gurney, CEO at Tetra Therapeutics shared his views on the results of the P-II exploratory study of BPN14770 in adult patients with Fragile X Syndrome.Shots:The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG…
March 1, 2021

Read more

Viewpoints_Ying Huang
VIEWPOINTS

PharmaShots Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends' collaboration with Janssen.Shots:The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were recently presented at the 62nd ASH MeetingThe…
February 25, 2021

Read more

Viewpoints_Dr. Sophia Randolph
VIEWPOINTS

PharmaShots Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework

In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology's collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors.Shots:Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination…
February 22, 2021

Read more

Viewpoints_Mathew L. Sherman
VIEWPOINTS

PharmaShots Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020Shots:Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…
February 17, 2021

Read more

Viewpoints_Bradley Galer
VIEWPOINTS

PharmaShots Interview: Zogenix’s Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

In an interview with PharmaShots, Bradley Galer, M.D., Chief Medical Officer at Zogenix shed light on data supporting the regulatory application and what the EU approval of Fintepla will mean in terms of reducing the high physical, emotional, and financial burden associated with the disease.Shots:Fintepla was approved by the EC in Dec'2020 as a new add-on therapy to…
February 16, 2021

Read more

Load more